NCT00817739View on ClinicalTrials.gov

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

PHASE2CompletedINTERVENTIONAL

Enrollment

341

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

September 30, 2005

Study Completion Date

December 31, 2008

Conditions

Prostatic Neoplasms

Interventions

DRUG

Leuprorelin

Leuprorelin injection

DRUG

Flutamide

Flutamide tablets

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT00817739 - Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c | Biotech Hunter | Biotech Hunter